Allakos (ALLK) Competitors $0.33 +0.00 (+0.12%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$0.33 0.00 (-0.09%) As of 05/1/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALLK vs. THTX, SLS, ENTA, EDIT, NLTX, PROC, NMRA, LXEO, TIL, and SNTIShould you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Theratechnologies (THTX), SELLAS Life Sciences Group (SLS), Enanta Pharmaceuticals (ENTA), Editas Medicine (EDIT), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), Neumora Therapeutics (NMRA), Lexeo Therapeutics (LXEO), Instil Bio (TIL), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry. Allakos vs. Theratechnologies SELLAS Life Sciences Group Enanta Pharmaceuticals Editas Medicine Neoleukin Therapeutics Procaps Group Neumora Therapeutics Lexeo Therapeutics Instil Bio Senti Biosciences Theratechnologies (NASDAQ:THTX) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings. Do analysts recommend THTX or ALLK? Allakos has a consensus target price of $2.00, suggesting a potential upside of 512.93%. Given Allakos' higher probable upside, analysts clearly believe Allakos is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 4.00Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Do insiders & institutionals believe in THTX or ALLK? 84.6% of Allakos shares are owned by institutional investors. 16.1% of Allakos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in THTX or ALLK? Allakos received 152 more outperform votes than Theratechnologies when rated by MarketBeat users. Likewise, 58.84% of users gave Allakos an outperform vote while only 54.39% of users gave Theratechnologies an outperform vote. CompanyUnderperformOutperformTheratechnologiesOutperform Votes3154.39% Underperform Votes2645.61% AllakosOutperform Votes18358.84% Underperform Votes12841.16% Does the media favor THTX or ALLK? In the previous week, Allakos had 1 more articles in the media than Theratechnologies. MarketBeat recorded 3 mentions for Allakos and 2 mentions for Theratechnologies. Allakos' average media sentiment score of 1.29 beat Theratechnologies' score of 0.43 indicating that Allakos is being referred to more favorably in the news media. Company Overall Sentiment Theratechnologies Neutral Allakos Positive Is THTX or ALLK more profitable? Allakos has a net margin of 0.00% compared to Theratechnologies' net margin of -3.75%. Theratechnologies' return on equity of 0.00% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets Theratechnologies-3.75% N/A -4.31% Allakos N/A -140.87%-86.22% Which has better valuation & earnings, THTX or ALLK? Theratechnologies has higher revenue and earnings than Allakos. Theratechnologies is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheratechnologies$88.67M1.51-$23.96M-$0.08-36.50AllakosN/AN/A-$185.70M-$1.32-0.25 Which has more risk and volatility, THTX or ALLK? Theratechnologies has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Allakos has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. SummaryAllakos beats Theratechnologies on 10 of the 18 factors compared between the two stocks. Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLK vs. The Competition Export to ExcelMetricAllakosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.49M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.167.3222.5118.54Price / SalesN/A241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.176.486.734.25Net Income-$185.70M$143.41M$3.22B$248.18M7 Day Performance-0.09%2.58%1.38%1.03%1 Month Performance1.56%5.00%2.79%2.70%1 Year Performance-70.34%-3.72%15.41%4.05% Allakos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLKAllakos4.6083 of 5 stars$0.33+0.1%$2.00+512.9%-71.1%$29.49MN/A-0.16190Upcoming EarningsShort Interest ↓Positive NewsTHTXTheratechnologiesN/A$2.55+1.2%N/A+124.6%$117.25M$88.67M-25.50140Short Interest ↑SLSSELLAS Life Sciences Group0.8083 of 5 stars$1.29-1.5%N/A+26.6%$117.19M$1M-1.8710ENTAEnanta Pharmaceuticals3.938 of 5 stars$5.23+2.5%$17.25+229.8%-55.4%$111.57M$66.59M-1.06160Upcoming EarningsNews CoveragePositive NewsEDITEditas Medicine4.1591 of 5 stars$1.33+3.9%$6.83+413.8%-70.4%$111.33M$32.31M-0.52230Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoverageNLTXNeoleukin TherapeuticsN/A$11.49+6.7%N/A-56.5%$107.98MN/A-3.6990Gap DownHigh Trading VolumePROCProcaps GroupN/A$0.95-40.3%N/A-65.8%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeNMRANeumora Therapeutics3.1363 of 5 stars$0.66+2.0%$9.29+1,306.9%-91.5%$106.75MN/A-0.35108LXEOLexeo Therapeutics2.5245 of 5 stars$3.21+18.5%$22.20+591.6%-61.7%$106.56M$650,000.00-1.0258Upcoming EarningsPositive NewsHigh Trading VolumeTILInstil Bio3.3763 of 5 stars$16.00+3.6%$114.00+612.5%+17.6%$104.94MN/A-1.38410Upcoming EarningsPositive NewsSNTISenti Biosciences2.8605 of 5 stars$3.97+2.3%$10.00+151.9%-14.5%$103.24M$2.56M-0.264Upcoming Earnings Related Companies and Tools Related Companies Theratechnologies Competitors SELLAS Life Sciences Group Competitors Enanta Pharmaceuticals Competitors Editas Medicine Competitors Neoleukin Therapeutics Competitors Procaps Group Competitors Neumora Therapeutics Competitors Lexeo Therapeutics Competitors Instil Bio Competitors Senti Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLK) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALLK Stock Free ALLK Stock Alerts